All In Biotech

Drug Trial Radar · NCT07052032

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Planned (sponsor's estimate)

Start

Jun 16, 2025

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Candid TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • CND261Biological

    CND261 will be dosed according to the assigned cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events through end of studyTime frame: Baseline to Month 12
  2. Changes from baseline in vital signs through end of studyTime frame: Baseline to Month 12
  3. Changes from baseline in ECG parameters through end of study: PR intervalTime frame: Baseline to Month 12
  4. Changes from baseline in ECG parameters through end of study: QRS intervalTime frame: Baseline to Month 12
  5. Changes from baseline in ECG parameters through end of study: QTcF intervalTime frame: Baseline to Month 12
  6. Changes from baseline in safety laboratory assessments through end of studyTime frame: Baseline to Month 12

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Candid Clinical Site

    Chisinau, Moldova

  • Candid Clinical Site

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.